These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 27133596)

  • 1. State of affairs: Design and structure-activity relationships of reversible P2Y12 receptor antagonists.
    Zetterberg F; Svensson P
    Bioorg Med Chem Lett; 2016 Jun; 26(12):2739-2754. PubMed ID: 27133596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effects and outcomes with new P2Y12 inhibitors in ACS.
    Collet JP; O'Connor S
    Fundam Clin Pharmacol; 2012 Feb; 26(1):16-8. PubMed ID: 21895760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors.
    Yanachkov IB; Chang H; Yanachkova MI; Dix EJ; Berny-Lang MA; Gremmel T; Michelson AD; Wright GE; Frelinger AL
    Eur J Med Chem; 2016 Jan; 107():204-18. PubMed ID: 26588064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of ticagrelor derivatives as novel antiplatelet agents.
    Zhang H; Liu J; Zhang L; Kong L; Yao H; Sun H
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3598-602. PubMed ID: 22546677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ticagrelor: oral reversible P2Y(12) receptor antagonist for the management of acute coronary syndromes.
    Cheng JW
    Clin Ther; 2012 Jun; 34(6):1209-20. PubMed ID: 22521881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure of the human P2Y12 receptor in complex with an antithrombotic drug.
    Zhang K; Zhang J; Gao ZG; Zhang D; Zhu L; Han GW; Moss SM; Paoletta S; Kiselev E; Lu W; Fenalti G; Zhang W; Müller CE; Yang H; Jiang H; Cherezov V; Katritch V; Jacobson KA; Stevens RC; Wu B; Zhao Q
    Nature; 2014 May; 509(7498):115-8. PubMed ID: 24670650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant Discovery of Tetrahydrothieno[3,2-c]pyridine-2-carboxamide Analogs as Potent P2Y12 Receptor Antagonists.
    Bhalekar SB; Shelke SN
    Chem Biodivers; 2019 Apr; 16(4):e1800550. PubMed ID: 30629808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling ligand recognition at the P2Y12 receptor in light of X-ray structural information.
    Paoletta S; Sabbadin D; von Kügelgen I; Hinz S; Katritch V; Hoffmann K; Abdelrahman A; Straßburger J; Baqi Y; Zhao Q; Stevens RC; Moro S; Müller CE; Jacobson KA
    J Comput Aided Mol Des; 2015 Aug; 29(8):737-56. PubMed ID: 26194851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of cyclopentyl-triazolol-pyrimidine (CPTP) based P2Y12 antagonists.
    Tu W; Fan J; Zhang H; Xu G; Liu Z; Qu J; Yang F; Zhang L; Luan T; Yuan J; Gong A; Feng J; Sun P; Dong Q
    Bioorg Med Chem Lett; 2014 Jan; 24(1):141-6. PubMed ID: 24332627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a New Morpholine Scaffold as a P2Y12 Receptor Antagonist.
    Ahn YH; Lee JY; Park HD; Kim TH; Park MC; Choi G; Kim S
    Molecules; 2016 Aug; 21(9):. PubMed ID: 27563870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P2Y12 receptors: structure and function.
    Cattaneo M
    J Thromb Haemost; 2015 Jun; 13 Suppl 1():S10-6. PubMed ID: 26149010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
    Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
    Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agonist-bound structure of the human P2Y12 receptor.
    Zhang J; Zhang K; Gao ZG; Paoletta S; Zhang D; Han GW; Li T; Ma L; Zhang W; Müller CE; Yang H; Jiang H; Cherezov V; Katritch V; Jacobson KA; Stevens RC; Wu B; Zhao Q
    Nature; 2014 May; 509(7498):119-22. PubMed ID: 24784220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is platelet inhibition correlated with time from last intake on P2Y12 blockers after an acute coronary syndrome? A pilot study.
    Deharo P; Quilici J; Bonnet G; Grosdidier C; Morange P; Alessi MC; Bonnet JL; Cuisset T
    Platelets; 2016 Dec; 27(8):791-795. PubMed ID: 27275528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients.
    Straub N; Beivers A; Lenk E; Aradi D; Sibbing D
    Thromb Haemost; 2014 Feb; 111(2):290-9. PubMed ID: 24154566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional testing methods for the antiplatelet effect of P2Y12 receptor antagonists.
    Price MJ; Barker CM
    Biomark Med; 2011 Feb; 5(1):43-51. PubMed ID: 21319964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clopidogrel: interactions with the P2Y12 receptor and clinical relevance.
    Dorsam RT; Murugappan S; Ding Z; Kunapuli SP
    Hematology; 2003 Dec; 8(6):359-65. PubMed ID: 14668029
    [No Abstract]   [Full Text] [Related]  

  • 19. Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on body weight in contrast to clopidogrel.
    Olivier CB; Schnabel K; Weber S; Zhou Q; Bode C; Moser M; Diehl P
    J Thromb Thrombolysis; 2016 Jul; 42(1):84-9. PubMed ID: 26837379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanism of action for reversible P2Y12 antagonists.
    Liu H; Ge H; Peng Y; Xiao P; Xu J
    Biophys Chem; 2011 May; 155(2-3):74-81. PubMed ID: 21440362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.